U.S. Patent Office pulls controversial rule to curb pharma patent abuse

Taking stock of the drug industry, from the lab to the medicine chest

December 4, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | U.S. Patent Office pulls controversial rule to curb pharma patent abuse "There was hard industry pushback against the rule," said Sean Tu, a West Virginia University law professor who studies pharma patent issues. By Ed Silverman 'Leptin's last chance': Mouse study says infamous weight loss drug failure could boost GLP-1s Mouse study published in Science Translational Medicine suggests an old approach to obesity, the leptin hormone, could improve efficacy of GLP-1 drugs. By Anil Oza STAT+ | Arrakis CEO cites 'cul-de-sacs' on road to RNA-intercepting cancer drugs Arrakis was formed with the idea of drugging RNA to fight cancer. Despite some promising data, CEO Michael Gilman is shifting targets. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser